Introduction
Fibreoptic bronchoscopy (FOB) is a common invasive pulmonary investigation providing direct visualization of the bronchial tree as far as the subsegmental bronchi, allowing diagnostic samples to be taken. FOB is a safe procedure with a complication rate of approximately 0.1%. Exclusion criteria include central cyanosis at rest, breathlessness, poorly controlled angina and recent myocardial infarction.
Patients with a low FEV, ('1 1) can be safely examined but sedation is usually withheld.
Introduction of the fibreoptic bronchoscope into the airways results in partial airway obstruction and reductions in oxygen saturation, measured by pulse oximetry, are recognized in patients undergoing endoscopic procedures using benzodiazepines and narcotics for sedation (l-3). Patients are usually monitored by clinical observation and with pulse oximetry (monitoring adequacy of arterial oxygenation) and supplemental oxygen is given via nasal cannulae. Failure of pulse oximetry to detect intra-and post-operative hypoventilation is recognized, especially with a high inspired oxygen concentration (4, 5) and marked hypoxaemia is sometimes difficult to detect clinically (6) . Elevated values of PaCO, are a better guide to type II respiratory failure secondary to alveolar hypoventilation, which is the mechanism induced by the procedure of FOB and/or the sedation. Transcutaneous PCOJPO, monitoring was introduced in the early 1980s using the principle that if an area of skin is warmed to 44°C dissolved gases diffuse through the skin. This technique is now widely used by anaesthetists in the operating theatre and on Intensive Care and Special Care Baby Units in the assessment of gas tensions in high-risk situations (7,X Intravenous diazepam suspension (Diazemuls; diazepam 10 mg12 ml), administered through an indwelling iv. catheter, was given at the beginning of the procedure to induce light sedation and throughout the bronchoscopy to keep the patient comfortable (mean total dose 7.60 mg; range 2.50-20.0 mg). Topical anaesthesia of the oropharynx and pharynx was obtained by spraying with xylocaine (2%).
The fibreoptic bronchoscope (Olympus BF20D) was passed orally under direct vision with the patient supine. Laryngeal and endobronchial anaesthesia was obtained by placing lignocaine 2% (mean dose 17.1 ml; range 6.0-26.0 ml) topically through the bronchoscope. Bronchoscopic washings were performed by passing 20 ml aliquots of normal saline through the bronchoscope with biopsies taken from lesions seen in the major airways. During the FOBS patients were also monitored continuously with ECG.
Prior to each investigation a new electrode membrane and electrolyte solution was applied and the transcutaneous PCO,IPO, monitors were calibrated against a standard concentration compressed gas (consisting of 5.0% carbon dioxide, 20.9% oxygen, 74.1% nitrogen), via the TCC3 Calibration Unit provided by Radiometer, as outlined by the manufacturer.
The transcutaneous electrodes were attached to the patient by an adhesive ring, over the pectoral region, with the temperature set at 44°C. The area was shaved (if necessary), minimally abraded and cleaned with alcohol. The 90% response times for the transcutaneous PCO, electrode was 50 s and for the PO, electrode 20 s, with continuous sampling.
The pulse oximeter's response time was 2 s with weighted average sampling every 6 s. Both the oximeter and the transcutaneous monitor printed their information using compact digital recorders by Radiometer, which provided real time recordings. The results of transcutaneous PCO,I PO, values were 'blinded' from the physician performing the FOB.
Ethical approval was provided by the local ethics committee and all patients gave written informed consent prior to the study.
Results
All subjects underwent uncomplicated FOB without any serious side-effects, with no patients requiring reversal of their sedation. The median duration of each FOB was 703 s (range 250-885 s) with 20 patients undergoing bronchial washings, 10 in combination with biopsy. All subjects received supplemental oxygen at rates varying between 2210 l/min via nasal cannulae.
Mean stable values of transcutaneous PCO, and PO, at rest prior to FOB were 5.8 (0.8) kPa and 8.6 (2.5) kPa respectively, with mean oxygen saturation (SpO,) of 93.6 (3.0)%. Corresponding mean arterial blood gas values of PaCO,, PaO, and oxygen saturation (SaO,) were 5.3 (0.6) kPa, IO.7 (3.5) kPa and 94.2 (3.0)% respectively ( Table 1) .
The FOBS were performed after a steady trace was obtained on both transcutaneous and pulse oximeter recordings, following the initial administration of oxygen. All events were timed from the first bolus injection of diazepam suspension, which was taken as time zero.
The median time for the bronchoscope to be passed into the trachea for the 22 patients was 185 s (range 855400 s) with median time to the first increase in transcutaneous PCO, (0.3 kPa or more) being 67 s (range lo-1800 s) following the diazepam. The median time to first reduction in transcutaneous PO, (0.3 kPa or more) was 120 s (range 26-560 s) and median time for the first reduction in oxygen saturation (2% or more) was 174 s (range 43-1332 s) ( Table  2 ). The levels of transcutaneous PO, and PCO, deteriorated more rapidly from baseline than corresponding oxygen saturations in 19 out of the 22 cases, with P-values of 0.035 and 0.046 respectively (independent samples t-test). The mean peak value of transcutaneous PCO, was 7.0 (1 .O) kPa with a mean difference in this peak compared with resting values of 1.3 (0.7) kPa. This difference is statistically significant with a P-value of <O.OOl (Student's paired t-test; Table 3 ). It took a median time of 372 s (range 6775940 s), for the transcutaneous PCO, to reach its peak and a median time of 951 s (range 2664440 s) to return to baseline levels. The varying flow rates of inspired oxygen, given in response to clinical need and/or oxygen The design of our study did not allow us to draw any conclusions about the increase in transcutaneous PCO, with diazepam dose, as the dosage was equated to the clinical need of the patient and not given incrementally. There was no statistical correlation between the increase in transcutaneous PCO, and the duration of the FOB or the values of FEV, used as independent variables.
Discussion
We found a significant increase in transcutaneous PCO, in patients undergoing FOB. This increase in transcutaneous PCO, occurred against a varying concentration of inspired oxygen, administered in response to reduced oxygen saturation and the patient's clinical need. The increase in transcutaneous PCO, implies alveolar hypoventilation induced by FOB with the combination of i.v. sedation, underlying lung disease and the insertion of the bronchoscope into the major airways. We observed the time taken to the first reduction in transcutaneous PO, and the first increase in transcutaneous PCO, (a change of at least 0.3 kPa from a steady baseline with the administration of supplemental oxygen via nasal cannulae) was quicker than the first reduction in oxygen saturation (at least 2% from baseline), in 19 of the 22 cases. This can be partly explained by extrapolation from the oxygen dissociation curve. In patients receiving supplemen- tal oxygen via nasal cannulae an inspired oxygen concentration of up to 68% can be generated if the patient is hypoventilating (9) which will increase the PaO, to greater than 13.3 kPa. With further hypoventilation the reduction in PaO, will need to be large to reduce the SpOZ, because of the sigmoid shape of the oxygen dissociation curve. The more rapid reduction in transcutaneous PO, than SpO, is made more interesting in view of the fact that the response times for the TCM3 transcutaneous PCOJPO, monitor are slower than the corresponding times for the OXImeter. When comparing the changes in oxygen saturation and transcutaneous PCO,IO, with the time taken to introduce the bronchoscope into the trachea and the duration of the bronchoscopy, it can be seen that many of these changes either precede or follow the brochoscopic procedure. Changes preceding the presence of the bronchoscope in the major airways can be explained by the effects of sedation in patients with underlying airways disease. The changes in oxygen saturation and transcutaneous PCO,/O, following the procedure is due to the sedation having a half-life greater than the duration of the bronchoscopy and the cessation of the sympathetic drive caused by the presence of the bronchoscope within the airways. Fibreoptic bronchoscopy (FOB) is a safe, established technique but patients undergoing FOB are at risk of type II respiratory failure. Sedation can cause hypoventilation during endoscopic procedures secondary to central respiratory depression (1,2) and this can be aggravated in FOB by the introduction of the bronchoscope into the major airways, leading to a reduction in the cross-sectional area with an increase in resistance to airflow. This is in contrast to patients undergoing upper gastrointestinal endoscopy, in whom the presence of the endoscope does not appear to contribute to the airway obstruction or endoscope-induced CO, retention (10) . Patients investigated for suspected lung cancer often have smoking-related obstructive airways disease which further increases the risk of procedural complications, but careful assessment can exclude patients at high risk.
Patients undergoing FOB are usually monitored with pulse oximetry. Maranetra (3) documented a reduction in oxygen saturation of l-25% (mean 5.6%) in 97 out of 100 patients undergoing FOB. Despite this, recent papers (45) have questioned the reliability of pulse oximetry as a monitoring technique in the presence of high inspired oxygen concentrations.
Oximetry measures the oxygenation of blood and will detect hypoxaemia, it can not detect hypercapnia and therefore the adequacy of ventilation. Alveolar hypoventilation, produced by sedation during FOB, leads to a rise in alveolar and arterial carbon dioxide tension and a reduction in alveolar oxygen tension with resultant hypoxaemia. When breathing room air the oxygen saturation will fall rapidly, giving a good indication of ventilatory status, but when the patient is receiving supplemental oxygen the alveolar PCO, will have to rise further to cause hypoxaemia which will result in significant desaturation.
In our study we used transcutaneous PCO,IPO, values to monitor respiratory status in patients undergoing FOB. Transcutaneous gas electrodes work on the principle that elevation of skin temperature (usually to 44°C) makes the skin permeable to gas diffusion by dissolving the lipid structure of dead, keratinized cells. This heating also increases cutaneous blood flow, arterializes the capillary blood and results in a shift in the oxygen dissociation curve to the right which amounts to a c. 6% increase in PO, per "C. This increase is offset by diffusion of oxygen out of the capillary loops and uptake of oxygen by,metabolically active cells. In the measurement of transcutaneous PCO, the increase in temperature increases the PCO, in blood by c. 4.8% per "C and CO, is also produced by living cells. These factors result in transcutaneous levels of PCO, being greater and PO, being lower than the corresponding arterial levels. These principles are based upon haemodynamically stable subjects with adequate skin perfusion.
The TCM3 transcutaneous PCO,IPO, electrode combines a Clark-type 0, electrode and a Severinghaus-type CO, electrode. The 0, electrode produces a current directly proportional to the 0, concentration against the outer membrane. The CO, electrode measures a voltage generated by hydrogen ions produced after the CO, diffuses across the membrane to produce hydrogen and bicarbonate ions. Prior to use the electrodes must be calibrated against a gas of fixed concentration (one-point calibration uses 5% CO,/20.9% 0, or two point calibration 10% CO,/90% N2). Transcutaneous levels of PO, and X0, are valid in their own right; they do not correspond directly to the arterial values but can reflect change in arterial gas tensions. There are no normal ranges for transcutaneous measurements and our calculations and conclusions are based on the observed trends in transcutaneous PCO,IPO,. The advantages of transcutaneous monitoring are the direct measurement of transcutaneous PCO, and PO, (important with high inspired oxygen concentrations) and a rapid response time. The disadvantages are that the procedure is time-consuming, requiring calibration, a 'warmup' period and electrode repositioning at 4 h due to drift from the calibrated baseline. As with oximetry, transcutaneous monitoring requires good skin perfusion and it is not known if the potential thermal damage and oedema caused by the electrode affects sensitivity and response time. Data calibrating transcutaneous values against arterial blood samples are based on studies with neonates and it is not known how transcutaneous monitoring compares in adults, disease states, anxiety and in response to medication.
This study highlights the limitations of pulse oximetry in detecting respiratory failure in patients undergoing fibreoptic bronchoscopy who are receiving supplemental oxygen. This problem can be overcome by using a transcutaneous PCO,IPO, monitor to assess the patient's respiratory status during the FOB. The clinical relevance of transcutaneous PCO,IPO, monitoring during FOB over clinical observation and pulse oximetry is uncertain as in this study no further adverse events were prevented by this monitoring, but no patients in this study were severely compromised or required reversal of their sedation. This study has not changed our clinical practice in that we continue to use pulse oximetry to monitor patients during bronchoscopy, rather than the more complex transcutaneous PCO, analysis, but we are aware of the limitations of oximetry and place greater emphasis on clinical evidence of hypoventilation.
